Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Diphenhydramine toxicity label warning for oral, topical products proposed by FDA.

This article was originally published in The Tan Sheet

Executive Summary

DIPHENHYDRAMINE TOXICITY LABEL WARNING PROPOSED BY FDA that would advise consumers not to use topical products containing the ingredient on chicken pox, poison ivy, sunburn, large areas of the body, blistered or oozing skin, more often than directed or with any other diphenhydramine-containing product, including those taken orally. FDA published the notice of proposed rulemaking in the Aug. 29 Federal Register. Written comments on the proposal are due by Nov. 28. A final rule would go into effect one year after publication.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087474

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel